$50M Penn-BioNTech fund backs first startup, Emvena
What's the deal? The $50 million Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund) has made its first investment, backing Emvena TherapeuticsDealroom has a profile for this one. Try Dealroom →. The undisclosed amount launches a biotech developing mRNA medicines that deliver treatments directly to the placenta for serious maternal and fetal conditions.
Why now? Managed by Osage University PartnersDealroom has a profile for this one. Try Dealroom →, the $50 million life sciences fund was launched in January to fill an early-stage financing gap for companies built on University of Pennsylvania research. Emvena, founded in 2026, is the first company it has both launched and financed.
What's the endgame? Emvena's lead program targets preeclampsia, a gestational complication affecting an estimated 2% to 8% of pregnancies worldwide and a leading cause of maternal and infant death. There is no approved therapy that addresses the underlying disease.
The technology comes from the lab of Michael J. Mitchell at Penn. In research published in Nature , his team showed a novel lipid nanoparticle preferentially delivers mRNA to the placenta, reducing disease severity in mouse models of preeclampsia.
Seed proceeds will advance the lead program toward investigational new drug (IND)-enabling studies and expand the platform into other maternal and fetal indications.
What could go wrong? The supporting evidence is preclinical. Emvena's lead program still needs IND-enabling work before any clinical testing, so the deal validates the fund's model, not the therapy itself.
"Emvena represents the kind of company the PxB Fund intends to catalyze and help build," said Anna Turetsky, general partner at the PxB Fund. Chief executive officer Young T. Kwon said the goal is "to build Emvena into a company that can bring meaningful new treatment options to mothers, babies, and the physicians who care for them."
The signal: The deal puts a university-to-startup model into practice at a time when biotech venture funding has rebounded but capital stays concentrated in later-stage rounds. By seeding a preclinical company in an underserved area, the fund is betting on the earliest, riskiest end of that market.
Read more: streetinsider.com
Image credit: Generated with Gemini
